COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection

COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection

In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO). The clinical course of the disease is unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to acute respiratory dist...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Katarzyna Kotfis, Kacper Lechowicz, Sylwester Drożdżal, Paulina Niedźwiedzka-Rystwej, Tomasz K. Wojdacz, Ewelina Grywalska, Jowita Biernawska, Magda Wiśniewska, Miłosz Parczewski
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2021-01-01
Sarja:Pharmaceuticals
Aiheet:
COVID-19
SARS-CoV-2
coronavirus
pandemic
spironolactone
potassium canrenoate
Linkit:https://www.mdpi.com/1424-8247/14/1/71

Internet

https://www.mdpi.com/1424-8247/14/1/71

Samankaltaisia teoksia